Rob Jones
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Prostate Cancer Treatment and Research 82
- Renal cell carcinoma treatment 33
- Prostate Cancer Diagnosis and Treatment 10
- Oncology 40
- PARP inhibition in cancer therapy 10
- Cancer Immunotherapy and Biomarkers 8
- Co-authors
- Johann Sebastian De Bono (18 shared papers)Karim S. Fizazi (16 shared papers)Howard I. Scher (8 shared papers)Cora Nanette Sternberg (5 shared papers)Fred Saad (9 shared papers)Kim N. Chi (4 shared papers)Christopher J. Logothetis (4 shared papers)Thian San Kheoh (4 shared papers)
- Journals
- Annals of Oncology (23 papers)The Lancet Oncology (13 papers)European Journal of Cancer (12 papers)European Urology (11 papers)The Lancet (10 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Rob Jones
221 papers receiving 21.4k citations
Rob Jones's Hit Papers
Peers
Comparison fields: 5 of 152
- Pulmonary and Respiratory Medicine 14.2k
- Oncology 3.2k
- Cancer Research 961
- Surgery 1.6k
- Immunology and Allergy 164
Countries citing papers authored by Rob Jones
This map shows the geographic impact of Rob Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob Jones more than expected).
Fields of papers citing papers by Rob Jones
This network shows the impact of papers produced by Rob Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob Jones. The network helps show where Rob Jones may publish in the future.
Co-authors
The 25 scholars most cited alongside Rob Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 227 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Abiraterone and Increased Survival in Metastatic Prostate Cancer Hit paper breakdown → | 2011 | 3648 |
| 2 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Hit paper breakdown → | 2015 | 1820 |
| 3 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2013 | 1585 |
| 4 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Hit paper breakdown → | 2015 | 1553 |
| 5 | Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Hit paper breakdown → | 2017 | 1368 |
| 6 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2012 | 1148 |
| 7 | Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Hit paper breakdown → | 2018 | 912 |
| 8 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2019 | 539 |
| 9 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 408 |
| 10 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Hit paper breakdown → | 2016 | 361 |
| 11 | Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2020 | 360 |
| 12 | Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 348 |
| 13 | Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) Hit paper breakdown → | 2014 | 329 |
| 14 | 2002 | 315 | |
| 15 | Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial Hit paper breakdown → | 2019 | 315 |
| 16 | 2018 | 275 | |
| 17 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol Hit paper breakdown → | 2021 | 263 |
| 18 | Genomics of lethal prostate cancer at diagnosis and castration resistance Hit paper breakdown → | 2019 | 256 |
| 19 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Hit paper breakdown → | 2022 | 240 |
| 20 | 2012 | 224 |
About Rob Jones
Rob Jones is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Cardiology and Cardiovascular Medicine, having authored 227 papers that have together received 21.9k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (82 papers), Bladder and Urothelial Cancer Treatments (34 papers), Renal cell carcinoma treatment (33 papers), PARP inhibition in cancer therapy (10 papers), Prostate Cancer Diagnosis and Treatment (10 papers), Cancer Immunotherapy and Biomarkers (8 papers), Chemotherapy-induced cardiotoxicity and mitigation (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (14.2k citations), Oncology (3.2k citations), Cancer Research (961 citations), Surgery (1.6k citations) and Immunology and Allergy (164 citations). Rob Jones has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Johann Sebastian De Bono, Karim S. Fizazi, Howard I. Scher, Cora Nanette Sternberg, Fred Saad, Kim N. Chi, Christopher J. Logothetis, Thian San Kheoh, Christopher M. Haqq and Arturo Molina. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, European Journal of Cancer, European Urology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.